A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · Aug 30, 2001

Keywords

ClinConnect Summary

In this open-label, strategic study patients are evaluated at Weeks 0, 1, 2, 4, 8, 12 to Week 48 after being treated on one of the following regimens:

Stavudine (d4T) + Didanosine (ddI) + Lamivudine (3TC) or d4T + ddI + Indinavir or d4T + ddI + Nevirapine.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients must have:
• • Diagnosed asymptomatic HIV infection.
• • HIV-1 RNA greater than 500 copies/ml.
• • CD4+ T-cell count greater than 200/mm3.
• • Never received antiretroviral therapy.
• • Exclusion Criteria
• Co-existing Condition:
• Excluded:
• • Severe non-HIV-related disease.
• Patients with the following prior conditions are excluded:
• • History of neuropathy.
• Prior Medication:
• Excluded:
• • Investigational drug within 1 month prior to study.
• • Immunomodulatory drug within 1 month prior to study.
• Prior Treatment:
• Excluded:
• • Radiation therapy within past month.
• • Chemotherapy within past month.